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Abstract
Introduction ISG15 is an ubiquitin-like molecule that is strongly
upregulated by type I interferons as a primary response to
diverse microbial and cellular stress stimuli. However,
alterations in the ISG15  signalling pathway have also been
found in several human tumour entities. To the best of our
knowledge, in the current study we present for the first time a
systematic characterisation of ISG15  expression in human
breast cancer and normal breast tissue both at the mRNA and
protein level.
Method Using semiquantitative real-time PCR, cDNA dot-blot
hybridisation and immunohistochemistry, we systematically
analysed ISG15 expression in invasive breast carcinomas (n =
910) and normal breast tissues (n = 135). ISG15  protein
expression was analysed in two independent cohorts on tissue
microarrays; in an initial evaluation set of 179 breast carcinomas
and 51 normal breast tissues; and in a second large validation
set of 646 breast carcinomas and 10 normal breast tissues. In
addition, a collection of benign and malignant mammary cell
lines (n = 9) were investigated for ISG15 expression.
Results ISG15 was overexpressed in breast carcinoma cells
compared with normal breast tissue, both at the RNA and
protein level. Recurrence-free (p  = 0.030), event-free (p  =
0.001) and overall (p  = 0.001) survival analyses showed a
significant correlation between ISG15  overexpression and
unfavourable prognosis.
Conclusion Therefore, ISG15  may represent a novel breast
tumour marker with prognostic significance and may be helpful
in selecting patients for and predicting response to the
treatment of human breast cancer.
Introduction
The interferon-stimulated gene 15 kDa (ISG15) is an inter-
feron-inducible ubiquitin-like protein. In addition to being stim-
ulated by type I interferon, expression of ISG15  is greatly
induced by viral or bacterial infection through the Janus
kinase/signal transducer and activator of transcription (Jak/
STAT) signalling pathway [1-3]. After induction, ISG15  is
secreted by monocytes, B- and T-lymphocytes and fibroblasts.
The ISG15 protein is made up of tandem ubiquitin homology
domains [4]. Within cells, ISG15 is covalently conjugated with
cellular proteins in an enzymatic pathway (so called ISGyla-
tion) comprised of the activating E1, conjugating E2 and ligat-
ing E3 enzymes, which are similar to those used by ubiquitin
(ubiquitylation). The conjugation of ISG15 with protein sub-
strates provides a tag that either marks the labelled protein for
degradation [5] or modulates its function [6]. Importantly,
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protein ISGylation is a reversible process, and removal of
ISG15 molecules is mediated by de-ISGylating enzymes [7].
Multiple target proteins of ISG15 have recently been identi-
fied, some of which have been implicated in the regulation of
immune responses. However, the biological consequences of
modification by ISG15  need to be determined further [8].
Interestingly, protein ubiquitylation has been shown to be of
fundamental importance in the regulation of both the innate
and adaptive immune systems, with roles in the control of
immune tolerance, the differentiation of T-cells and the intrac-
ellular signal transduction induced by antigen, cytokines or toll-
like receptor ligands [9].
So far, little is known about the function of ISG15 in carcino-
genesis. ISG15 is a post-translational protein modifier and
also a secreted cytokine. Each of these roles has been impli-
cated in carcinogenesis, although ISG15  was recently
thought to function as an oncogene as well as a tumour-sup-
pressor gene [10]. Enhanced ISGylation was observed in
response to cancer chemotherapeutics, suggesting that
ISG15 has a tumour-suppressing function. Moreover, ISG15
is a target of the tumour-suppressor gene TP53 [11]. In con-
trast, deregulated overexpression of ISG15  and enhanced
ISGylation were positively correlated with cancerogenesis
underlining the oncogenic potential of ISG15 [12-14]. As a
secreted protein, ISG15 has been shown to primarily modu-
late immune cell activation [15].
Some of the ISG15 target proteins also have functions in the
cell nucleus including chromatin remodelling and polymerase
II transcription [16]. Interestingly, in bladder cancer immuno-
histochemistry revealed that ISG15  was located predomi-
nantly in the nuclei of cancer cells which were associated with
an advanced tumour stage [12]. Surprisingly, ISG15 overex-
pression in human bladder cancer has not been found to be
associated with a general inflammatory response even though
ISG15 was expected to be stimulated by interferon primarily in
an inflammatory process. Therefore, ISG15  expression in
bladder cancer suggests that it is specifically associated with
tumour cells [12].
In breast cancer, ISG15 expression has so far only been exam-
ined in benign and malignant human breast cell lines [13]. To
the best of our knowledge, this is the first study to systemati-
cally analyse the expression of ISG15 in human breast carci-
nomas and normal breast tissues both at the mRNA and the
protein level. We analysed the results particularly in correlation
to clinicopathological data, such as hormone receptor status,
HER2 status and patient survival data, in order to validate
ISG15 as a new prognostic marker and potential drug target
in the treatment of human breast cancer.
Materials and methods
ISG15 protein expression was assessed in two independent
cohorts of breast cancer patients using tissue microarrays
(TMAs). The first tumour cohort has been previously described
[17] and consisted of 179 breast cancer tissue specimens
and 51 normal breast tissue specimens. The TMA used one
tissue core from non-selected, formalin-fixed, paraffin-embed-
ded primary breast cancer specimens from patients diag-
nosed between 1994 and 2002 at the Institute of Pathology,
University of Regensburg, Germany. The patients' ages
ranged from 25 to 82 years with a median age of 56 years. An
experienced surgical pathologist (AH) evaluated slides of all
specimens, stained with haematoxylin and eosin (H&E), before
construction of the TMA in order to identify representative
tumour areas. Histologically, all tumours were graded accord-
ing to criteria by Elston and Ellis [18]. Clinical follow-up data,
provided by the German Central Tumour Registry were availa-
ble for all 179 breast cancer patients with a median follow-up
period of 78 months (range 0 to 148 months). The Institutional
Review Board of the participating centres approved the study.
The second TMA for validation consisted of 967 breast spec-
imens, of which it was possible to analyse 646 breast carcino-
mas and 10 normal breast tissues samples. The second TMA
was constructed from a cohort of breast cancer patients who
were participants of a case-controlled trial for the assessment
of breast cancer susceptibility markers and prognostic factors,
the Bavarian Breast Cancer Cases and Controls (BBCC),
which has been described previously, including methods for
the data collection [19,20]. The database for this analysis
closed on 31 December, 2007 and had a median follow up of
4.7 years. Paraffin embedded tissue was available for 967
BBCC patients. Briefly a 0.6 mm punch was retrieved from the
breast cancer tumour after a pathologist (AD) evaluated H&E-
stained slides of all specimens. Data about the hormone
receptor status were obtained from original pathological
reports of these specimens; the other data were collected
from the patients' medical records.
The collection of paraffin-embedded and formalin-fixed normal
(n = 14) and cancerous (n = 25) breast tissue samples for the
mRNA expression analysis has been described previously
[21].
Cell lines
The human mammary epithelial cell lines HMEC and MCF12A,
and the breast cancer cell lines MCF7, T47D, ZR75-1, MDA-
MB231, MDA-MB468, SKBR3 and BT20 were obtained from
the ATCC (Rockville, MD, USA) and cultured as previously
described [22].
RNA extraction and reverse transcription
Total RNA was isolated using the TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer's recom-
mendations. For paraffin-embedded tissues, five consecutiveAvailable online http://breast-cancer-research.com/content/10/4/R58
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sections (each 5 μm thick) were prepared, deparaffinised and
conventionally re-hydrated in a decreasing alcohol-series
before RNA extraction. Of the obtained RNA, 1 μg was
reverse transcribed using the Reverse Transcription System
(Promega, Madison, WI, USA). In order to improve the tran-
scription rate oligo-dT was mixed with pdN6 primers at a ratio
of 1:2.
Semiquantitative real-time PCR
Semiquantitative PCR was performed using the LightCycler
system with the LightCycler DNA Master SYBR Green I Kit
(Roche Diagnostics, Mannheim, Germany) as previously
described [22]. To ensure the accuracy of the experiment, all
reactions were performed in triplicate. Primer sequences used
were:ISG15 sense 5'- GAG AGG CAG CGA ACT CAT CT -
3' and antisense 5'- CTT CAG CTC TGA CAC CGA CA -3';
GAPDH sense 5'- GAA GGT GAA GGT CGG AGT CA -3'
and antisense 5'- AAT GAA GGG CTC ATT GAT GG -3'. The
annealing temperature for both genes was 60°C. Reaction
specificity was controlled by post-amplification melting curve
analyses and gel electrophoresis of the obtained products.
Breast cancer cDNA dot-blot hybridisation
The breast cancer profiling array (BD Clontech, Heidelberg,
Germany) contains 50 pairs of cDNAs generated from
matched tumourous and normal breast tissue samples from
individual patients and three breast cancer lymph node metas-
tasis specimens, spotted on a nylon membrane [23]. Hybridi-
sations using 25 ng of a gene-specific 32P-labelled cDNA
probe digested from Unigene cDNA clones were conducted
according to the manufacturer's recommendations. The
tumour/normal intensity ratio was calculated using a STORM-
860 phosphoimager (Molecular Dynamics, Sunnyvale, CA,
USA) and normalised against the background.
Immunohistochemical studies for the expression of HER2 uti-
lised an avidin-biotin peroxidase method with a 3,3'-diami-
nobenzidine chromatogen. After antigen retrieval (microwave
oven for 30 minutes at 200W) immunohistochemistry studies
were performed in a NEXES immunostainer (Ventana, Tucson,
AZ, USA) according to the manufacturer's instructions. The
primary antibodies used were anti-HER2 (DAKO, Hamburg,
Germany; 1:400), anti-oestrogen receptor (ER) and anti-pro-
gesterone receptor (PR) (Novocastra, Newcastle Upon Tyne,
UK; 1:20). For target proteins, the ChemMate detection kit
(DAKO, Hamburg, Germany) was used. A surgical pathologist
(AH) performed a blinded evaluation of the TMA slides with no
knowledge of clinical data. It was not possible to interpret
some results for reasons that included a lack of tumour tissue
and the presence of necrosis or crush artefacts. HER2 expres-
sion was scored according to the DAKO HercepTest. For the
evaluation of the presence of ER and PR, a semiquantitative
immunoreactivity score (IRS), as described by Remmele and
Stegner [24], was used.
ISG15 Immunohistochemistry
The TMAs of both the evaluation set and the validation set
were subjected to immunostaining using the Advance Kit
(K4068, DAKO, Hamburg, Germany) following the manufac-
turer's instructions. Paraffin-embedded breast carcinomas
were used as positive controls. After deparaffinisation and
rehydration the tissue samples were heated in a microwave
oven for 30 minutes at 200W in 10 mM sodium citrate buffer
(pH 7.2). Endogenous peroxidase was blocked by peroxidase-
blocking solution (S2023, DAKO, Hamburg, Germany) for 10
minutes. The polyclonal primary antibody ISG15 (AP 1150a,
rabbit, Abgent, San Diego, CA, USA) was applied (1:30 dilu-
tion) for 30 minutes at room temperature. The primary antibody
was omitted in the negative controls. For signal detection 3,3'-
diaminobenzidine was used. Slides were counterstained with
H&E and after dehydration mounted in Vitro-Clud (Langen-
brinck, Emmendingen, Germany). Two experienced patholo-
gists (NB, AN) scored the immunohistochemical staining
intensity according to the scoring system suggested by Rem-
mele and Stegner [24].
Statistical methods
For statistical evaluation SPSS version 14.0 (SPSS Inc, Chi-
cago, IL) was used. Differences were considered statistically
significant when p < 0.05. A non-parametrically two-tailed
Mann-Whitney U-test was employed to analyse differences in
expression levels. For analysis of the cancer profiling array, a
Kolmogorov-Smirnov test was applied to test for a normal
value distribution, followed by a two-sided paired t-test to ana-
lyse differences in normal and tumour expression. A statistical
association between clinicopathological and molecular param-
eters was tested for using a two-sided Fisher's exact test.
Recurrence-free survival (RFS) and overall survival (OS) were
calculated according to the Kaplan-Meier equation.
For the BBCC-TMA, RFS was defined as any local recurrence
or distant recurrence, whatever occurred first. Event-free sur-
vival (EFS) was defined as any local recurrence, distant recur-
rence or death, whatever occurred first. Kaplan-Meier
estimates were used to display the survival curves and log-
rank test was used to compare patients with high vs. low
ISG15 expression. For multivariate analyses, a Cox propor-
tional hazard model was constructed for OS, EFS and RFS.
Results
Upregulation of ISG15 in human breast cancer cell lines
We started the study by investigating the level of ISG15
mRNA expression in non-malignant and malignant human
mammary cell lines. Real-time PCR analysis revealed a low
ISG15 mRNA expression among the non-malignant mammary
epithelial cell lines HMEC and MCF12A, whereas ISG15
mRNA transcript levels varied more and in summary were
clearly elevated in the cancerous cell lines BT20, MDA-
MB468, MDA-MB231, T47D and MCF7, of which MCF7 dis-
played an exceptionally high level of ISG15 mRNA (Figure 1).Breast Cancer Research    Vol 10 No 4    Bektas et al.
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The median elevation of ISG15 expression in malignant cell
lines vs. non-malignant cell lines was 2.5-fold and these differ-
ences in expression between the respective groups were sta-
tistically significant (p  = 0.043, Mann-Whitney U-test).
Differences in expression levels between ER-positive and ER-
negative breast cancer cell lines were statistically not
significant.
Upregulation of ISG15 in primary breast cancers 
analysed by real-time PCR
Next we analysed ISG15 mRNA expression in primary breast
cancers (n = 25) and normal mammary samples (n = 14)
derived from formalin-fixed, paraffin-embedded tissues by real-
time PCR. In line with our breast cell line data, ISG15 mRNA
was abundantly expressed in primary breast cancer speci-
mens when compared with normal mammary epithelial tissue
(Figure 2). The median fold change of ISG15 upregulation in
the cancerous tissue vs. normal tissue was 10.3 and differ-
ences in expression between the two groups were statistically
significant (p = 0.002, Mann-Whitney U-test).
Correlation between ISG15 mRNA expression and 
protein expression
We additionally analysed 10 paraffin-embedded breast carci-
nomas and corresponding normal breast tissues by both sem-
iquantitative real-time PCR and immunohistochemistry in order
to correlate mRNA and protein levels in the same tumour sam-
ples as well as in the corresponding normal breast tissues.
ISG15 mRNA was significantly upregulated in breast cancer
specimens when compared with the corresponding normal
breast tissues (p = 0.003, Mann-Whitney U-test). The median
change in the tumour was three-fold compared with normal
breast tissue on ISG15 mRNA level. At the protein level as
determined by immunohistochemistry ISG15  was overex-
pressed in the tumour and correlated with upregulation of
ISG15 mRNA. The median IRS in the tumour was five com-
pared with an IRS of two in normal breast tissue and differ-
ences between the groups were statistically significant (p <
0.01, Mann-Whitney U-test) (Figure 3).
Upregulation of ISG15 in primary breast cancer analysed 
by cDNA dot-blot hybridisation
ISG15 upregulation was validated by dot-blot analysis on a
nylon array containing spotted cDNAs derived from 50
matched pairs of normal and cancerous breast tissue (Figure
Figure 1
Abundance of the expression of ISG15 mRNA in breast cancer cell  lines Abundance of the expression of ISG15 mRNA in breast cancer cell 
lines. Semiquantitative real-time PCR (LightCycler) of ISG15 expres-
sion was performed on reverse transcribed RNA from non-malignant 
(white bars) and malignant cell lines (black bars). ISG15 mRNA expres-
sion was low among the non-malignant mammary epithelial cell lines 
HMEC and MCF12A, whereas ISG15 mRNA transcript levels varied 
more and in summary were elevated in the investigated cancerous cell 
lines.
Figure 2
Upregulation of ISG15 mRNA in primary breast cancer Upregulation of ISG15 mRNA in primary breast cancer. A collection of paraffin-embedded breast carcinomas (T; n = 25) and normal breast tissues 
(N; n = 14) was analysed for ISG15 expression by semiquantative real-time PCR. ISG15 was strongly upregulated at the transcript level in the 
tumourous tissues compared with the normal breast tissues.Available online http://breast-cancer-research.com/content/10/4/R58
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4). The cancer profiling array showed upregulation (fold
change ≥ 2) of ISG15 in 33 of 50 primary breast tumours
(66%), as well as in one of three metastatic lymph nodes, com-
pared with matched normal breast tissue (two-sided paired t-
test: p < 0.001). Mean densitometric intensity in normal tis-
sues was 1533 arbitrary units (standard deviation [SD] ± 995)
and 3571 arbitrary units (SD ± 2292) in tumour tissues.
Overexpression of ISG15 protein in primary breast 
carcinomas
Two independent cohorts of breast cancer specimens
arranged on two different TMAs were analysed for ISG15
expression by immunohistochemistry. These represented an
initial evaluation set, consisting of 179 breast carcinomas and
51 normal breast tissues, and an independent validation set,
consisting of 646 breast carcinomas and 10 normal breast tis-
sues. In normal breast tissue ISG15  expression was often
absent or weak (Figure 5a, b). In ductal carcinoma in situ (Fig-
ure 5c, d) ISG15 expression was more intense than in normal
breast tissue. In invasive breast carcinomas (Figure 5e, f, duc-
tal type) ISG15 expression was generally more abundant than
in either ductal carcinoma in situ or normal breast tissue. In
tubular breast carcinomas (Figure 5g, h), a less frequent vari-
ant of invasive breast carcinomas with a more favourable prog-
nosis than invasive ductal breast carcinomas, ISG15
expression was less abundant than in most invasive ductal
breast carcinomas.
Statistical analysis of the initial evaluation TMA cohort
Statistical data of the initial TMA cohort are presented in Addi-
tional files 1, 2, 3, 4. In the initial TMA cohort, ISG15 protein
expression in breast carcinomas (IRS > 4) was associated
with the ER status (p = 0.028), but not with tumour size, lymph
node status, histological grading, focality or histological type
of tumour (Additional file 3). To investigate a possible impact
of ISG15 overexpression on clinical outcome we calculated
univariate survival probability curves with respect to immuno-
histochemical results. We found that ISG15  expression in
breast cancer (IRS > 4) showed an unfavourable prognosis
with regard to RFS as shown by Kaplan-Meier analysis (p =
0.012) (Additional file 1, Additional file 4). Patients who
showed abundant ISG15 expression in the tumour had an
estimated mean RFS of 112 months (95% confidence interval
[CI]: 99 to 125) compared with 78 months (95% CI: 68 to 87)
in patients with negative/weak ISG15 expression. Although
OS was not significantly associated with ISG15 overexpres-
sion, there was a trend towards unfavourable prognosis in
those patients with strong ISG15 expression (Additional file 2,
Additional file 4). Possibly due to a weak association with the
ER status, ISG15 expression could not be identified as an
independent prognostic factor in a multivariate analysis in this
breast cancer cohort.
Figure 3
Correlation between ISG15 mRNA and protein expression Correlation between ISG15 mRNA and protein expression. An additional collection of paraffin-embedded breast carcinomas (T; n = 10) and corre-
sponding normal breast tissues (N; n = 10) was analysed for ISG15 expression by semiquantitative real-time PCR and immunohistochemistry in the 
same samples. ISG15 mRNA upregulation correlated with ISG15 protein expression in the same tumour sample (T) compared with the correspond-
ing normal breast tissue (N). Magnification: 400×.Breast Cancer Research    Vol 10 No 4    Bektas et al.
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Validation in the Bavarian breast cancer cases and 
controls tissue microarray cohort
To confirm our results from the initial evaluation set of tumours,
we analysed a second larger cohort (from BBCC) of breast
cancer specimens on a TMA. In this validation cohort the IRS
score was available for 646 invasive breast cancer cases. The
mean IRS score was 3.5 with 83.9% (n = 542) of tumours
having a low score of zero to four and 16.1% (n = 104) show-
ing abundant expression of ISG15 (IRS > 4). As in the initial
set we found a close association between ISG15 expression
and an unfavourable prognosis (that is hazard ratio (HR) =
1.94; 95% CI: 1.17 to 3.23; p = 0.01 in OS analysis). How-
ever, this cohort of tumours was divided into two groups of
similar size for efficient correlation analysis. Therefore, the val-
idation set of the additional 646 breast tumours was divided
into low ISG15 expressers (IRS = 0 to 3; n = 333) and high
ISG15 expressers (IRS = 4 to 12; n = 313). Under this slightly
different cut-off level (IRS > 3), the prognostic value of ISG15
expression was improved, as ISG15  immunohistochemical
expression was also an independent predictor for OS and EFS
in multivariate analysis (Table 1 and Figures 6 and 7). Further-
more, under this cut-off level, clear associations could be seen
between ISG15 expression and both tumour size and grading
(Table 2).
Discussion
ISG15 is a type I interferon regulated gene that is induced as
a primary response to diverse microbial and cell stress stimuli
[10]. Although the biological activities of ISG15 have yet to be
elucidated, it is thought that ISG15 plays an important role in
host defence and stress response pathways that have
antitumour functions [10]. Consistent with this view, altera-
tions in the ISG15 pathway have been identified in human
tumours and in tumour cell lines. Increased expression of free
and conjugated ISG15 has been exhibited in human breast,
ovarian, prostate, colorectal and melanoma tumour cell lines
compared with normal cell lines [13]. In accordance with the
work of Desai and colleagues [13], who analysed two cell lines
and showed abundant expression of ISG15 in the breast can-
cer cell line ZR-75-1 but not in the BT474 cell line, we also
found upregulation of ISG15  mRNA in several additional
breast cancer cell lines analysed (that is, BT20, MDA-MB468,
MDA-MB231, T47D and MCF7) when compared with the
benign mammary cell lines HMEC and MCF12A. Interestingly,
upregulation of ISG15 was highly abundant in the breast can-
cer cell line MDA-MB231, a cell line shown to be highly meta-
static in nude mouse models [25]. This could implicate a
possible association between ISG15  upregulation and
enhanced proliferation or invasiveness of cancer cells.
In agreement with the findings of ISG15  upregulation in
diverse tumour cell lines in culture, microarray analyses of
human tumour biopsies have revealed enhanced expression of
ISG15 in pancreatic adenocarcinoma [14], endometrial can-
cer [13] and bladder cancer [12], when compared with the
respective normal tissues. Expression of ISG15 in human can-
cerous and normal breast tissue has not been previously ana-
lysed. In the current study, a systematic characterisation of
ISG15 expression in human breast cancer cells is presented
for the first time at both the mRNA and the protein level, and
includes a large cohort of breast carcinoma specimens that
have been analysed by correlative analysis using clinicopatho-
logical parameters and patient survival data.
In accordance with previous findings in human cancer tissue
[12-14] we found upregulation of ISG15 at the mRNA level in
breast carcinomas compared with normal breast tissue.
Enhanced expression of ISG15 in breast cancer was further
validated by cDNA dot-blot analysis. Overexpression of ISG15
protein in breast carcinomas could be confirmed by immuno-
histochemistry of a TMA. Using this technique, ISG15 protein
expression was correlated with patient survival data. In the ini-
tial cohort of breast carcinomas (n = 179) we found a signifi-
cant correlation between ISG15 expression and unfavourable
prognosis (RFS; p = 0.012) suggesting a potential role of
ISG15 in breast cancer development. Analysis of the second,
Figure 4
Expression profiles were determined using cDNA dot-blot hybridisation analysis (BD Clontech) containing cDNA pairs derived from 50 matched nor- mal breast tissues (N), tumourous breast tissues (T) and three lymph node metastastic tissues (marked with arrows) Expression profiles were determined using cDNA dot-blot hybridisation analysis (BD Clontech) containing cDNA pairs derived from 50 matched nor-
mal breast tissues (N), tumourous breast tissues (T) and three lymph node metastastic tissues (marked with arrows). Upregulation of ISG15 was 
observed in primary breast tumours and in one of three metastatic lymph nodes, as compared with matched normal breast tissue.Available online http://breast-cancer-research.com/content/10/4/R58
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independent breast cancer cohort (n = 967) confirmed this.
I0n the validation TMA set, patients with ISG15 overexpres-
sion (IRS > 3) showed unfavourable prognosis in RFS (p =
0.03), EFS (p = 0.001) and OS analyses (p = 0.001). This
unfavourable prognosis of patients with abundant ISG15
expression might be due to an insufficient response to chem-
otherapy in this subgroup of patients. Indeed, deregulated
ISG15 expression has been found in response to diverse can-
cer chemotherapeutic agents, such as paclitaxel in the treat-
ment of ovarian carcinomas and 5-fluorouracil in the therapy of
oesophageal cancer [26,27]. Bani and colleagues [26] ana-
lysed mice with human ovarian carcinoma xenografts undergo-
ing treatment with paclitaxel as a way of understanding the in
vivo molecular consequences of drug treatment. By analysing
expression changes by cDNA microarray they found that pacl-
itaxel could affect the level of expression of a variety of genes
in those ovarian tumours responding to treatment. So the
expression of several interferon-inducible genes such as
ISG15 was reduced in the responders. Surprisingly, in human
oesophageal squamous cancer cell lines, ISG15 was found to
be upregulated after treatment with the chemotherapeutic
agent 5-fluorouracil as shown by DNA microarray analysis and
reverse transcription-PCR [27]. ISG15 mRNA expression was
also found to be upregulated after treatment of human color-
ectal and breast cancer cell lines with campothecin, a topoi-
somerase I inhibitor [28,29]. Therefore ISG15  may be
regulated differentially in response to different chemothera-
peutic regimens.
Interestingly, ISG15 expression was associated with ER sta-
tus in the initial TMA set (p = 0.028; Additional file 3), but not
in the validation TMA set (p = 0.177, Table 2), as oestrogen is
known to play a modulatory role in the ISGylation pathway.
Indeed the ligating (E3) enzyme, that is a part of the post-trans-
lational modification by ISG15, was shown to be oestrogen-
responsive [30]. The so-called ISGylation is mediated by a
multi-step pathway, comprised of activating (E1), conjugating
(E2) and ligating (E3) enzyme components [30]. The oestro-
gen responsiveness of the ligating (E3) enzyme in the ISGyla-
tion pathway is of great importance because ERs play a major
role in the regulation of growth, survival and differentiation of
normal and malignant breast epithelial cells [31,32]. There-
fore, the determination of breast tumour hormone receptor sta-
tus is of major importance for therapy selection [33].
Approximately 60 to 80% of all breast cancers abundantly
express ERα, but only two-thirds of those patients are respon-
sive to endocrinal treatment (anti-oestrogen therapy). Intrigu-
ingly, a proportion of ERα-positive tumours do not respond to
hormone treatment at all (de novo resistance) while the major-
ity of those tumours that initially responded to anti-oestrogens
eventually become resistant during treatment (acquired resist-
ance). Most ER-resistant tumours remain ERα-positive, sug-
gesting a continued role for ERα in breast cancer cell survival
and proliferation [34,35]. The likely development of ER-resist-
ance during breast cancer treatment with anti-oestrogens
emphasises the urgent need for surrogate target molecules
that may be able to bypass these resistances. Therefore,
ISG15 might be a target molecule in the therapy of drug-
resistant breast tumours.
Conclusion
Our analyses showed ISG15 overexpression in human breast
carcinomas relative to normal breast tissue at the RNA and
protein level indicating that ISG15 may represent a candidate
oncogene in human breast cancer. Interestingly, ISG15 could
Figure 5
Immunohistochemical expression of ISG15 in normal breast tissue, and  in non-invasive and invasive breast tumours using a tissue microarray Immunohistochemical expression of ISG15 in normal breast tissue, and 
in non-invasive and invasive breast tumours using a tissue microarray. 
(a, b) Normal breast tissue lacks ISG15 expression (IRS = 0). (c, d) In 
ductal carcinoma in situ ISG15 expression is more intense (IRS = 8) 
than in normal breast tissue. (e, f) In invasive breast carcinomas (here: 
ductal type) ISG15 expression was clearly more abundant (example 
shows staining with an IRS = 12) compared with normal breast tissue 
and ductal carcinoma in situ. (g, h) In tubular breast carcinomas (IRS = 
4), a less frequent variant of invasive breast carcinomas with a more 
favourable prognosis than invasive ductal breast carcinomas, ISG15 
expression was less abundant than in most invasive ductal breast carci-
nomas and stronger than in most normal breast tissues. Magnifications: 
a, c, e, g: 100×; b, d, f, h: 400×.Breast Cancer Research    Vol 10 No 4    Bektas et al.
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function as a novel breast tumour marker with prognostic or
predictive significance. Recently, microarray experiments
determined strong deregulation of ISG15  expression in
response to diverse cancer chemotherapeutic agents, for
example, paclitaxel in the treatment of ovarian carcinomas or 5-
fluorouracil in the therapy of oesophageal cancer. These find-
ings indicate that ISG15 could represent a predictive biomar-
ker in the treatment of these cancers as well. However, the
putative function of ISG15 in breast carcinogenesis and in
chemotherapeutic response has to be further analysed in pro-
spective studies. As a next step we will investigate whether an
ISG15-based diagnostic assay is able to predict response to
specific chemotherapy regimens in the treatment of breast
cancer.
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Table 1
Cox proportional hazard ratio analysis of the validation set (variables were categorised as indicated in Table 2)
n Overall Survival 
Adjusted hazards 
ratio (95% CI)
p-value Event-free survival 
Adjusted hazards 
ratio (95% CI)
p-value Recurrence-free 
survival Adjusted 
hazards ratio 
(95% CI)
p-value
Age < 50 153 1 1 1
50–59 154 1.19 (0.54 to 
2.63)
0.659 1.15 (0.67 to 
1.96)
0.622 1.20 (0.69 to 
2.09)
0.516
60–69 158 1.45 (0.71 to 
2.97)
0.309 0.99 (0.59 to 
1.67)
0.978 0.81 (0.46 to 
1.43)
0.475
≥ 70 106 3.43 (1.76 to 
6.69)
0.0003 1.94 (1.17 to 
3.22)
0.010 1.17 (0.64 to 
2.14)
0.612
pTa T1 297 1 1 1
T2-4 274 3.56 (1.89 to 
6.67)
0.00008 2.88 (1.85 to 
4.50)
0.000003 3.258 (1.95 to 
5.43)
0.000006
pNa 03 3 51 1 1
1 236 2.81 (1.64 to 
4.82)
0.0002 2.149 (1.43 to 
3.23)
0.0002 2.52 (1.57 to 
4.04)
0.0001
Grading 1 or 2 385 1 1 1
3 186 1.39 (0.82 to 
2.36)
0.218 1.05 (0.69 to 
1.59)
0.832 1.17 (0.73 to 
1.88)
0.513
Hormone 
receptor status
Negative 123 1 1 1
Positive 448 0.55 (0.32 to 
0.95)
0.032 0.726 (0.47 to 
1.13)
0.160 0.77 (0.46 to 
1.26)
0.287
ISG15 Low (IRS 0 to 3) 277 1 1 1
High (IRS 4 to 12) 294 1.78 (1.07 to 
2.95)
0.025 1.516 (1.03 to 
2.22)
0.033 1.39 (0.90 to 
2.13)
0.135
aAccording to Sobin LH, Wittekind CH: UICC: TNM Classification of Malignant Tumours. 6th edition, New York: Wiley; 2002. [36]. CI, Confidence 
intervalAvailable online http://breast-cancer-research.com/content/10/4/R58
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Table 2
Association of ISG15 immunoreactivity with clinical and pathological characteristics assessed in clinical routine examination of the 
validation set
Characteristic Low ISG15 (Score 0 to 3) High ISG15 (Score 4 to 12) Total n (%) p-value
Total 333 (51.5) 313 (48.5) 646 (100) n/a
Age (t-test) Mean (± SD) 57.3(± 12.2) 59.2 (± 12.4) 58.2 (± 12.3) 0.053
Total 333 313 646
Age < 50 91 (52.3) 83 (47.7) 174 (100) 0.05
50–59 108 (59.3) 74 (40.7) 182 (100)
60–69 80 (45.7) 95 (54.3) 175 (100)
≥ 70 54 (47.0) 61 (53.0) 115 (100)
total 333 (51.5) 313 (48.5) 646 (100)
pTa pT1 185 (56.9) 140 (43.1) 325 (100) 0.006
PT2 to 4 139 (45.9) 164 (54.1) 303 (100)
Total 324 (51.6) 304 (48.4) 628 (100)
pNa pN0 193 (52.9) 172 (47.1) 365 (100) 0.504
pN1 134 (50.2) 133 (49.8) 267 (100)
Total 327 (51.7) 305 (48.3) 632 (100)
Grading 1 or 2 240 (55.0) 196 (45.0) 436 (100) 0.007
3 90 (43.7) 116 (56.3) 206 (100)
Total 330 (51.4) 312 (48.6) 642 (100)
Hormone receptor Status Negative 54 (43.2) 71 (56.8) 125 (100) 0.177
Positive 234 (50.0) 234 (50.0) 468 (100)
Total 288 (48.6) 305 (51.4) 593 (100)
aAccording to Sobin LH, Wittekind CH: UICC: TNM Classification of Malignant Tumours. 6th edition, New York: Wiley; 2002 [36]. SD, Standard deviation; n/a, not 
available; pT, Pathological assessment of the primary tumour; pN, Pathological assessment of the regional lymph nodes.Breast Cancer Research    Vol 10 No 4    Bektas et al.
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Additional files
Figure 6
Correlation of ISG15 expression and patient prognosis according to  univariate Kaplan-Meier analysis Correlation of ISG15 expression and patient prognosis according to 
univariate Kaplan-Meier analysis. Breast cancer patients overexpressing 
ISG15 show unfavourable prognosis in overall survival analysis (p = 
0.001).
Figure 7
Correlation of ISG15 expression and patient prognosis according to  univariate Kaplan-Meier analysis Correlation of ISG15 expression and patient prognosis according to 
univariate Kaplan-Meier analysis. Breast cancer patients overexpressing 
ISG15 exhibit unfavourable prognosis in event-free survival (p = 
0.001).
Figure 8
Correlation of ISG15 expression and patient prognosis according to  univariate Kaplan-Meier analysis Correlation of ISG15 expression and patient prognosis according to 
univariate Kaplan-Meier analysis. Breast cancer patients overexpressing 
ISG15 have an unfavourable prognosis in recurrence-free survival anal-
ysis (p = 0.030).
The following Additional files are available online:
Additional file 1
Tif file that shows the correlation of ISG15 expression 
and patient prognosis according to univariate Kaplan-
Meier analysis in the initial TMA set. Breast cancer 
patients expressing ISG15 exhibit an unfavourable 
prognosis in recurrence-free survival analysis (p = 
0.012).
See http://www.biomedcentral.com/content/
supplementary/bcr2117-S1.tiff
Additional file 2
Tif file that shows correlation of ISG15 expression and 
patient prognosis according to univariate Kaplan-Meier 
analysis in the initial TMA set. Breast cancer patients 
expressing ISG15 show a trend towards unfavourable 
prognosis in overall survival analysis (p = 0.128).
See http://www.biomedcentral.com/content/
supplementary/bcr2117-S2.tiff
Additional file 3
Word file containing a table presenting the 
clinicopathological and immunohistochemical 
parameters in relation to ISG15 immunoreactivity in the 
initial TMA set.
See http://www.biomedcentral.com/content/
supplementary/bcr2117-S3.docAvailable online http://breast-cancer-research.com/content/10/4/R58
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